The reporter learned from the National Health Insurance Administration that since December last year, the National Health Insurance Administration has concentrated on comprehensive management of central intravenous drug delivery prices, and by treating consumable prices, standardizing service prices, and improving the accessibility of central intravenous drug delivery devices and services.
Central intravenous administration is a method of directly inputting drugs through large veins near the heart, such as the veins below the neck and clavicle. It is not only necessary for chemotherapy for tumor patients, but also for elderly and frail patients who rely on nutritional support for a long time. According to statistics, about 3 million patients nationwide use central intravenous drug delivery devices every year. For a long time, the price of consumables for central intravenous administration has been significantly higher and the burden on patients is heavy. At the same time, the cost of implantation of medical services in infusion ports in various places has also been high and low, with large differences. In response to this, the National Health Insurance Administration has concentrated on comprehensive management of central intravenous drug delivery prices.
Jiang Bingzhen, head of the Medical Price Department of the Price Craft and Cooking Department of the National Health Insurance Administration: We focus on the inflated water caused by excessive price increase in the middle of the circulation field. We guided the medical insurance bureaus of various provinces to hold talks with many companies, mainly to urge them to actively reduce the price increase in the circulation link, appropriately adjust terminal prices, and benefit patients. This does not involve brand replacement, which means that we maintain the diversity of the entire clinical use product.
Relevant person in charge of the National Health Insurance Administration introduced that the price reduction space mainly comes from the overall compression of price moisture in the intermediate circulation link, which is conducive to fair competition in the market and has limited impact on manufacturers.
Jiang Bingzhen, head of the Medical Price Department of the Price Certification and Production Department of the National Medical Insurance Administration: After the treatment, the overall cost of central IV catheterization has dropped from about 850 yuan to about 450 yuan. The overall cost of central venous catheterization through peripheral vascular puncture has dropped from about 3,000 yuan to about 1,300 yuan, and the overall cost of infusion port has dropped from more than 6,000 yuan to more than 1,300 yuan, and the patient's cost burden will be greatly reduced.
